Lexicon Pharmaceuticals (LX31) Stock Price & Analysis
LX31 Stock Chart & Stats
- Day’s Range
- EUR 0.99 - EUR 1.03
- 52-Week Range
- EUR 0.95 - EUR 1.40
- Previous Close
- EUR 1.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 570.01M
- Enterprise Value
- EUR 919.00M
- Total Cash (Recent Filing)
- EUR 190.61M
- Total Debt (Recent Filing)
- EUR 59.28M
- Price to Earnings (P/E)
- ―
- Beta
- 1.59
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet
The move to zero reported debt and higher equity reduces financial risk and gives Lexicon greater flexibility to fund clinical development and commercialization. This stronger balance-sheet position can extend strategic runway and support execution through important late-stage milestones.
SONATA-HCM Progress
Completing and significantly over-enrolling the SONATA-HCM Phase III study strengthens the evidence-generation process for a major late-stage program. Greater enrollment may improve study power and supports a defined path toward an important clinical readout and potential product value creation.
Pipeline And Regulatory Progress
Progress toward the FDA-required STENO1 exposure level and a planned Zynquista NDA resubmission represent meaningful regulatory advancement. If execution remains on track, this could move a key asset closer to approval while expanding Lexicon’s potential commercial opportunity.
Bears Say
Persistent Cash Burn
Consistently negative operating and free cash flow show that Lexicon’s operations do not yet fund development needs internally. Continued cash burn increases reliance on existing liquidity or external financing and could constrain investment capacity if profitability does not improve.
Volatile Revenue Base
The sharp decline from a small and volatile revenue base indicates that current commercial or partner revenue is not yet dependable. Limited recurring revenue makes financial performance sensitive to licensing timing and increases the importance of successful product launches and milestones.
Ongoing Unprofitability
Very high gross margins have not translated into profitability because the revenue base remains too small to absorb operating and development costs. Persistent net losses weaken earnings quality and leave Lexicon dependent on future pipeline success to establish sustainable operating leverage.
LX31 FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
What is Lexicon Pharmaceuticals’s market cap?
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
How were Lexicon Pharmaceuticals’s earnings last quarter?
Is Lexicon Pharmaceuticals overvalued?
Does Lexicon Pharmaceuticals pay dividends?
What is Lexicon Pharmaceuticals’s EPS estimate?
How many shares outstanding does Lexicon Pharmaceuticals have?
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Lexicon Pharmaceuticals Stock Smart Score
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael S. Exton
- Employees
- 81
- Website
- www.lexpharma.com
- Address
- 2445 Technology Forest Boulevard, The Woodlands, TX, 77381, US
Lexicon Pharmaceuticals (LX31) Earnings & Revenues
LX31 Company Deck
LX31 Earnings Call
Earnings Call SentimentPositive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.
View all DE:LX31 earnings summariesLX31 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 10 |
| Technical Analysis | 3 | 4 | 1 |
| Moving Averages | 2 | 1 | 9 |
